Stock Research for ARTH

ARTH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ARTH Stock Chart & Research Data

The ARTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARTH Due diligence Resources & Stock Charts

The ARTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARTH Detailed Price Forecast - CNN Money CNN View ARTH Detailed Summary - Google Finance
Yahoo View ARTH Detailed Summary - Yahoo! Finance Zacks View ARTH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ARTH Trends & Analysis - Trade-Ideas Barrons View ARTH Major Holders - Barrons
NASDAQ View ARTH Call Transcripts - NASDAQ Seeking View ARTH Breaking News & Analysis - Seeking Alpha
Spotlight View ARTH Annual Report - CompanySpotlight.com OTC Report View ARTH OTC Short Report - OTCShortReport.com
TradeKing View ARTH Fundamentals - TradeKing Charts View ARTH SEC Filings - Bar Chart
WSJ View Historical Prices for ARTH - The WSJ Morningstar View Performance/Total Return for ARTH - Morningstar
MarketWatch View the Analyst Estimates for ARTH - MarketWatch CNBC View the Earnings History for ARTH - CNBC
StockMarketWatch View the ARTH Earnings - StockMarketWatch MacroAxis View ARTH Buy or Sell Recommendations - MacroAxis
Bullish View the ARTH Bullish Patterns - American Bulls Short Pains View ARTH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ARTH Stock Mentions - StockTwits PennyStocks View ARTH Stock Mentions - PennyStockTweets
Twitter View ARTH Stock Mentions - Twitter Invest Hub View ARTH Investment Forum News - Investor Hub
Yahoo View ARTH Stock Mentions - Yahoo! Message Board Seeking Alpha View ARTH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ARTH - SECform4.com Insider Cow View Insider Transactions for ARTH - Insider Cow
CNBC View ARTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARTH - OTC Markets
Yahoo View Insider Transactions for ARTH - Yahoo! Finance NASDAQ View Institutional Holdings for ARTH - NASDAQ


Stock Charts

FinViz View ARTH Stock Insight & Charts - FinViz.com StockCharts View ARTH Investment Charts - StockCharts.com
BarChart View ARTH Stock Overview & Charts - BarChart Trading View View ARTH User Generated Charts - Trading View




Latest Financial News for ARTH


Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
Posted on Thursday December 06, 2018

Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, presented an update on its corporate milestones, plans and timetables at the LD Micro Main Event XI in Los Angeles, California. Chief Executive Officer, Terrence W. Norchi, MD provided the following summary.


Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
Posted on Tuesday December 04, 2018

FRAMINGHAM, Mass., Dec. 04, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.


Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
Posted on Wednesday November 28, 2018

Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has submitted the required documents for AC5™ Topical Hemostat (AC5)1 to its Notified Body as it seeks a CE mark, which is a next step on the path to commercialization in countries governed by the European Medical Devices Directive (MDD). This first such submission by Arch to a European regulatory body follows the recent submission of a 510(k) premarket notification to the US Food and Drug Administration. Receipt of a CE mark would allow AC5 to be commercialized for use on external wounds, and in particular, for controlling bleeding by mechanically sealing areas of leakage and managing wounds in skin.


Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
Posted on Monday November 26, 2018

Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Main Event XI. Chief Executive Officer, Terrence W. Norchi, MD will deliver a corporate presentation on Tuesday, December 4 at 12:00 PM Pacific Time in Track 1.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.